Global Biologics Market

Biologics Market Size, Share, Growth Analysis, By Product(Monoclonal Antibodies, Vaccines, Recombinant Growth Factors, Recombinant Proteins), By Source(Microbial, Mammalian, and Others), By Application(Diagnostic, Therapeutic, Protein Purification, and Others), By Disease(Oncology, Cardiovascular, Immunological Diseases, Infectious Diseases), By Manufacturing(Outsourced, and In-house), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2127 | Region: Global | Published Date: June, 2024
Pages: 219 |Tables: 62 |Figures: 75

Biologics Market Insights

Global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031).

Biologic drugs are complex in nature and are produced through biotechnological processes, often involving recombinant DNA technology. The purpose of the biologics market is to provide innovative and effective therapies for various diseases and medical conditions. Biologics have revolutionized the treatment landscape, offering targeted and personalized approaches for patients. They are widely used in the treatment of chronic diseases like cancer, autoimmune disorders, and infectious diseases. The market aims to develop and deliver biologics that improve patient outcomes and enhance the quality of life. The driving factors behind the growth of the biologics market is the increasing prevalence of chronic diseases worldwide. The rise in diseases such as cancer, diabetes, and rheumatoid arthritis has created a significant demand for biologics. the need for specialized storage and transportation conditions for biologics, as they are sensitive to temperature and environmental conditions. Maintaining the integrity and stability of biologics throughout the supply chain can be complex and costly.

The global biologics market plays a vital role in providing innovative therapies for various diseases. It aims to improve patient outcomes and enhance the quality of life. While there are driving factors such as the increasing prevalence of chronic diseases and advancements in biotechnology, there are also restraining factors like high costs and complex manufacturing processes. Overcoming these challenges and capitalizing on opportunities in personalized medicine and emerging technologies will shape the future of the biologics market.

US Biologics Market is poised to grow at sustainable CAGR for the next forecast year

Market Snapshot - 2024-2031

Global Market Size

USD 462 Billion

Largest Segment

Microbial

Fastest Growth

Microbial

Growth Rate

10.40% CAGR

Global Biologics Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Biologics Market Segmental Analysis

The global biologics market is segmented by product, source, application, disease, manufacturing, and region. By product, the market can be segmented into Monoclonal Antibodies, Vaccines, Recombinant Growth Factors, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Synthetic Immunomodulators, Antisense & RNAi, Therapeutics, and Other. By source, the market is segmented into microbial, mammalian, and others. By application, the market is segmented into Diagnostic, Therapeutic, Protein Purification, and Others. By disease, the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, metabolic diseases. By manufacturing, the market is segmented into outsourced, and in-house. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.  

Analysis by Source 

In 2023, the microbial segment held the largest market share of 58.23% in the biologics industry. The majority of approved biologics available today are developed and manufactured using microbial expression systems. Key products, including platelet-derived growth factor, recombinant insulin, granulocyte-macrophage colony-stimulating factor, and recombinant interferons, are produced through microbial expression systems. 

The mammalian expression systems segment is anticipated to exhibit significant growth during the forecast period. These expression systems are primarily utilized for developing recombinant proteins and viral-vector based vaccines. Among mammalian cell lines, CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) are the most commonly employed. Notable biologic products manufactured using mammalian expression systems include Perjeta (Pertuzumab), Adcetris (Brentuximab-Vedotin), Shingrix (zoster vaccine), Kadycla (Trastuzumab emtansine), and Aimovig (erenumab). 

In 2023, microbial was the largest market segment with a share of 58 percent. The survey results showed that 23% of the participants worked in the biologics industry. Currently, the most used and approved class of biologics is produced by microbial expression systems. Some of the major products of microbial expression systems include platelet-derived growth factor, recombinant insulin, granulocyte-macrophage colony-stimulating factor, and recombinant interferons. 

According to the research, the mammalian expression systems segment is likely to experience a rapid growth during the forecast period. These expression systems have mainly been employed for producing recombinant proteins and viral vector-based vaccines. Note that the most frequently used mammalian cell lines include CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney).  

Analysis by Manufacturing 

In 2023, the in-house segment dominated the biologics market with a share of 84.87%. Biologic drug manufacturing is more complex compared to small molecules, involving the use of live microorganism cultures and adherence to strict regulatory requirements. In-house manufacturing offers the advantage of direct control, enabling better day-to-day monitoring of biologic drugs. 

The outsourcing segment is projected to grow at a compound annual growth rate (CAGR) of 10.7% during the forecast period. Several Contract Development and Manufacturing Organizations (CDMOs) like WuXi Biologics, Lonza, and Samsung Biologics have established state-of-the-art biologic manufacturing facilities. Collaborating with these CDMOs provides companies access to manufacturing experts, ensuring successful downstream process development and the implementation of new technologies. The growth of the market is greatly influenced by the increasing number of CDMOs and their expansion of production capacity. For example, in November 2023, WuXi Biologics inaugurated its integrated biologics center in Shanghai, a vast facility spanning 1.6 million square feet. This center will provide end-to-end biologics development facilities, including product development, quality control, and manufacturing.

Global Biologics Market By Source, 2022 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Biologics Market Regional Insights

In 2022, North America held the largest share of 44.37% in the biologics market. This can be attributed to several factors. Firstly, the region has a high prevalence of chronic diseases, driving the demand for biologic therapies. Additionally, North America is home to numerous leading pharmaceutical companies, contributing to the growth of the market. Favorable reimbursement policies and substantial investments in research and development further support the market's expansion. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the United States. The increasing share of biologic prescriptions and investments in targeted drug development are key factors driving market growth. Moreover, the approval of novel biologic drugs such as gene therapy, antisense, and RNAi therapeutics is expected to propel the market even further.

Asia Pacific is projected to grow at a CAGR of 11.0% during the forecast period. The region is experiencing a rising burden of diseases like cancer, diabetes, and cardiovascular diseases, coupled with an increase in the geriatric population. This has led to an increased demand for biologics in the region. Market leaders in the industry are actively focusing on meeting this demand and making significant investments in the development of advanced biologic products. The adoption of biosimilars is also driving market growth in the Asia Pacific region, as they enhance the accessibility and affordability of biologic therapies.

Global Biologics Market By Geography, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Biologics Market Dynamics

Biologics Market Drivers

Increasing Prevalence of Chronic Diseases

  • The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes has been a significant driver for the biologics market. Biologics offer targeted and personalized treatments for these conditions, leading to improved patient outcomes. For example, in 2022, the U.S. Food and Drug Administration (FDA) approved several biologics for the treatment of various cancers, including Keytruda (pembrolizumab) and Opdivo (nivolumab).

Advancements in Biotechnology

  • Technological advancements in the field of biotechnology have propelled the growth of the biologics market. Innovations in genetic engineering, recombinant DNA technology, and cell therapy have enabled the development of more sophisticated and effective biologic drugs. Notably, the approval of gene therapies such as Luxturna (voretigene neparvovec) for inherited retinal disease and Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy exemplify the progress made in this field.

Biologics Market Restraints

High Cost of Biologics

  • The high cost associated with the development, manufacturing, and distribution of biologics remains a significant restraint for market growth. The complex manufacturing processes, stringent regulatory requirements, and expensive research and development efforts contribute to the elevated prices of biologic drugs. This can limit accessibility and affordability, particularly in developing regions.

Regulatory Challenges

  • The biologics market is subject to stringent regulatory oversight, which can pose challenges for market players. Regulatory agencies such as the FDA and the European Medicines Agency (EMA) require comprehensive testing, clinical trials, and documentation to ensure the safety and efficacy of biologic drugs. Meeting these regulatory standards can be time-consuming and costly, potentially slowing down the approval process and hindering market growth.

Request Free Customization of this report to help us to meet your business objectives.

Biologics Market Competitive Landscape

The global biologics market is characterized by intense competition among key market players striving to maintain their market position and gain a competitive edge. The market is dominated by major pharmaceutical companies, biotechnology firms, and contract manufacturing organizations (CMOs) that specialize in biologic drug development and manufacturing. Biotechnology firms also play a significant role in the competitive landscape. Companies like Biogen, Genentech, and Gilead Sciences focus on developing cutting-edge biologics and investing in research to advance scientific understanding and therapeutic options. Biogen's multiple sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made substantial contributions to their market presence.

Biologics Market Top Player’s Company Profiles

  • Amgen (US)
  • Novartis (Switzerland)
  • Pfizer (US)
  • Merck & Co. (US)
  • AstraZeneca (UK)
  • Bristol Myers Squibb (US)
  • Sanofi (France)
  • Eli Lilly and Company (US)
  • Gilead Sciences (US)
  • Biogen (US)
  • Celgene (US)
  • Novo Nordisk (Denmark)
  • Takeda Pharmaceutical Company (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (UK)
  • Boehringer Ingelheim (Germany)
  • Vertex Pharmaceuticals (US)

Biologics Market Recent Developments

  • In January 2023, Johnson & Johnson announced that it would acquire Momenta Pharmaceuticals for US$6.5 billion. Momenta is a leading developer of biosimilars, and the acquisition will help Johnson & Johnson expand its biosimilars portfolio.
  • In February 2023, AbbVie announced that it would acquire Allergan for US$63 billion. Allergan is a leading developer of biologics, and the acquisition will help AbbVie expand its biologics portfolio.
  • In March 2023, Novartis announced that it would acquire AveXis for US$8.7 billion. AveXis is a leading developer of gene therapies, and the acquisition will help Novartis expand its gene therapy portfolio.

Biologics Key Market Trends

  • Rising Focus on Personalized Medicine: Personalized medicine, also known as precision medicine, is gaining traction in the biologics market. The approach involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors. Advances in genomics and molecular diagnostics have enabled the identification of specific biomarkers and genetic mutations, leading to the development of targeted biologic therapies. For instance, the approval of drugs like Keytruda and Herceptin (trastuzumab) that target specific genetic mutations in cancer patients exemplify the trend towards personalized medicine.
  • Growing Adoption of Biosimilars: Biosimilars, which are highly similar to reference biologic drugs in terms of safety, efficacy, and quality, are gaining increased acceptance in the market. Biosimilars offer a more affordable alternative to expensive biologic therapies, promoting wider accessibility for patients. As a result, the market has witnessed the introduction of several biosimilars in recent years, including Truxima (rituximab), a biosimilar to Rituxan, and Amjevita (adalimumab-atto), a biosimilar to Humira.

Biologics Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

Our global biologics market analysis states that this industry is expected to experience significant growth during the forecast period from 2023 to 2030. The market refers to the industry that focuses on the development, manufacturing, and commercialization of biologic drugs. Biologics are medicines derived from living organisms, such as proteins, antibodies, vaccines, and gene therapies. They offer targeted and personalized treatments for various diseases, including cancer, autoimmune disorders, and rare genetic conditions. The market analysis of the biologics industry involves studying various factors that impact its growth and performance. These factors include market size, revenue trends, market share, and competitive landscape. Market analysis also involves assessing the demand and supply dynamics, pricing trends, regulatory environment, and technological advancements in the industry. The biologics market has witnessed significant growth in recent years due to factors such as the increasing prevalence of chronic diseases, advancements in biotechnology, and rising investments in research and development. Factors influencing regional market growth include the presence of the market analysis of the global biologics market involves assessing various factors that contribute to its growth, understanding the competitive landscape, and evaluating regional dynamics. This analysis helps stakeholders in the industry make informed decisions, identify growth opportunities, and develop effective strategies to navigate the evolving market landscape.

Report Metric Details
Market size value in 2022 USD 462 Billion
Market size value in 2031 USD 1125.55 Billion
Growth Rate 10.40%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Product
    • Monoclonal Antibodies, Vaccines, Recombinant Growth Factors, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Synthetic Immunomodulators, Antisense & RNAi, Therapeutics, and Other
  • Source
    • Microbial, Mammalian, and Others
  • Application
    • Diagnostic, Therapeutic, Protein Purification, and Others
  • Disease
    • Oncology, Cardiovascular, Immunological Diseases, Infectious Diseases, Metabolic Diseases, Hematological diseases, Others
  • Manufacturing
    • Outsourced, and In-house
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Amgen (US)
  • Novartis (Switzerland)
  • Pfizer (US)
  • Merck & Co. (US)
  • AstraZeneca (UK)
  • Bristol Myers Squibb (US)
  • Sanofi (France)
  • Eli Lilly and Company (US)
  • Gilead Sciences (US)
  • Biogen (US)
  • Celgene (US)
  • Novo Nordisk (Denmark)
  • Takeda Pharmaceutical Company (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (UK)
  • Boehringer Ingelheim (Germany)
  • Vertex Pharmaceuticals (US)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Biologics Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Biologics Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biologics Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biologics Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Biologics Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031).

The global biologics market is characterized by intense competition among key market players striving to maintain their market position and gain a competitive edge. The market is dominated by major pharmaceutical companies, biotechnology firms, and contract manufacturing organizations (CMOs) that specialize in biologic drug development and manufacturing. Biotechnology firms also play a significant role in the competitive landscape. Companies like Biogen, Genentech, and Gilead Sciences focus on developing cutting-edge biologics and investing in research to advance scientific understanding and therapeutic options. Biogen's multiple sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made substantial contributions to their market presence. 'Roche (Switzerland)', 'Johnson & Johnson (US)', 'AbbVie (US)', 'Amgen (US)', 'Novartis (Switzerland)', 'Pfizer (US)', 'Merck & Co. (US)', 'AstraZeneca (UK)', 'Bristol Myers Squibb (US)', 'Sanofi (France)', 'Eli Lilly and Company (US)', 'Gilead Sciences (US)', 'Biogen (US)', 'Celgene (US)', 'Novo Nordisk (Denmark)', 'Takeda Pharmaceutical Company (Japan)', 'Bayer (Germany)', 'GlaxoSmithKline (UK)', 'Boehringer Ingelheim (Germany)', 'Vertex Pharmaceuticals (US)'

The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes has been a significant driver for the biologics market. Biologics offer targeted and personalized treatments for these conditions, leading to improved patient outcomes. For example, in 2022, the U.S. Food and Drug Administration (FDA) approved several biologics for the treatment of various cancers, including Keytruda (pembrolizumab) and Opdivo (nivolumab).

Rising Focus on Personalized Medicine: Personalized medicine, also known as precision medicine, is gaining traction in the biologics market. The approach involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors. Advances in genomics and molecular diagnostics have enabled the identification of specific biomarkers and genetic mutations, leading to the development of targeted biologic therapies. For instance, the approval of drugs like Keytruda and Herceptin (trastuzumab) that target specific genetic mutations in cancer patients exemplify the trend towards personalized medicine.

In 2022, North America held the largest share of 44.37% in the biologics market. This can be attributed to several factors. Firstly, the region has a high prevalence of chronic diseases, driving the demand for biologic therapies. Additionally, North America is home to numerous leading pharmaceutical companies, contributing to the growth of the market. Favorable reimbursement policies and substantial investments in research and development further support the market's expansion. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the United States. The increasing share of biologic prescriptions and investments in targeted drug development are key factors driving market growth. Moreover, the approval of novel biologic drugs such as gene therapy, antisense, and RNAi therapeutics is expected to propel the market even further.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biologics Market

Product ID: SQMIG35H2127

$5,300
BUY NOW GET FREE SAMPLE